Status:
COMPLETED
Chromium and Insulin Action
Lead Sponsor:
Pennington Biomedical Research Center
Conditions:
Type 2 Diabetes
Eligibility:
All Genders
25-75 years
Phase:
PHASE4
Brief Summary
The effect of Chromium to improve glucose levels in diabetes is controversial. The hypothesis of the study was to evaluate the effect of supplementing the diet of individuals with Type 2 diabetes with...
Detailed Description
The primary clinical strategy to improve metabolic control in patients with Type 2 diabetes consists of lifestyle modification combined with pharmacologic intervention. However, alternative strategies...
Eligibility Criteria
Inclusion
- Type 2 diabetes on diet therapy or low dose oral agent -
Exclusion
- Significant cardiovascular, hepatic or renal disease
- \-
Key Trial Info
Start Date :
August 1 1998
Trial Type :
INTERVENTIONAL
End Date :
April 1 2003
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00283777
Start Date
August 1 1998
End Date
April 1 2003
Last Update
April 8 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Vermont
Burlington, Vermont, United States, 05410